Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of CD5024 1% in Acne Vulgaris

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. The subject is a male or a female aged from 18 to 35 years old at screening visit.~2. The subject has a medical diagnosis of acne vulgaris :~   2.1 at least 20 (twenty) inflammatory lesions and a maximum of 100 (one hundred) non-inflammatory lesions (nose is excluded for the lesion count) at Baseline~   2.2 symmetry of the lesions: No more than twice as many acne lesions on one side as compared to the other side at Baseline~3. If the subject is a female of childbearing potential, she must agree to use an effective contraceptive method for the duration of the study~Exclusion Criteria:~1. The subject has an underlying known disease surgical or medical condition, in the opinion of the investigator might interfere with interpretation of the study results or put the subject at risk (e.g., other dermatological diseases affecting the treatment area, such as a dermatitis, eczema, etc., or any uncontrolled chronic or serious diseases which would normally prevent participation in any clinical study, such as a cancer, leukemia or severe hepatic impairment), (Screening).~2. The subject has acne conglobata, acne fulminans, secondary acne (chloracne, drug-induced acne, etc.), nodulo cystic acne, or acne requiring systemic treatment.~3. The subject has a known or suspected allergies or sensitivities to any components of any of the study drugs (see Investigator's Brochure/Product label).~4. The subject is a male with beard or facial hair, which would interfere with clinical evaluation or clinical procedure (Screening and Baseline).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- CD5024 1% cream (Type: EXPERIMENTAL): Active drug;
- CD5024 cream placebo (Type: PLACEBO_COMPARATOR): Placebo of active drug;
- CD0271/CD1579 gel (Type: OTHER): Positive control;
- CD0271/CD1579 gel placebo (Type: OTHER): Placebo of positive control;

Based on this trial design, predict the completion outcome and termination type (if applicable).